- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05753384
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
March 19, 2024 updated by: Poitiers University Hospital
Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Tyrosine kinase inhibitors (TKI) have revolutionized the management and prognosis of chronic myeloid leukemia (CML).
Daily treatment with TKI, which is necessary due to lack of cure, is frequently associated with moderate, chronic and sometimes severe adverse effects.
The ability to permanently stop treatment with TKI has thus become a major goal in CML to prevent the occurrence of adverse events, improve quality of life and reduce the general cost of the treatment; we talk about Treatment Free Remission (TFR).
It now remains to be demonstrated in a comparative prospective study that a strategy of de-escalation of the TKI treatment dose before treatment discontinuation optimizes TFR results.
At the same time, it is possible to reduce adverse reactions and improve the quality of life of patients.
In this context, the investigator propose to conduct a randomized clinical trial including CML patients, allowing to compare the results of TFR at 24 months between a sudden stop of treatment after a maintenance phase of dosage for 12 months and a de-escalation arm of dose (dosage reduced by 50%) for 12 months before stopping.
A secondary immunological translational objective of this project will be to compare the quantitative and qualitative evolution of innate CD8 T cells between the 2 arms (abrupt cessation of ITK treatment versus progressive withdrawal) and look for a predictive innate CD8 T cells blood signature at the time of stopping treatment of a successful TFR in both arms.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
140
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emilie Cayssials-Caylus, Dr
- Phone Number: c
- Email: emilie.cayssials@chu-poitiers.fr
Study Locations
-
-
-
Angers, France
- Recruiting
- CHU Angers
-
Contact:
- Corentin ORVAIN, Dr
-
Bayonne, France
- Recruiting
- CH Bayonne
-
Contact:
- Fréderic BAUDUER, Dr
-
Brest, France
- Recruiting
- CHU Brest
-
Contact:
- Jean Christophe IANOTTO, Dr
-
Créteil, France
- Recruiting
- CHI Créteil
-
Contact:
- Lydia ROY, Dr
-
La Rochelle, France
- Recruiting
- CH La Rochelle
-
Contact:
- Emmanuel FLECK, Dr
-
Lille, France
- Recruiting
- CHU Lille
-
Contact:
- Valerie COITEUX, Dr
-
Limoges, France
- Recruiting
- CHU Limoges
-
Contact:
- Amélie PENOT, Dr
-
Lyon, France
- Recruiting
- Centre Leon Berard
-
Contact:
- Franck NICOLINI, Dr
-
Mont-de-Marsan, France
- Recruiting
- CH Mont de Marsan
-
Contact:
- Samia MADENE HAROUNE, DE
-
Nantes, France
- Recruiting
- CHU Nantes
-
Contact:
- Viviane DUBRUILLE, Dr
-
Poitiers, France
- Recruiting
- CHU Poitiers
-
Contact:
- José Miguel TORREGROSA DIAZ, DR
-
Périgueux, France
- Recruiting
- Ch Perigueux
-
Contact:
- Claire CALMETTE, Dr
-
Toulouse, France
- Recruiting
- Oncopole Toulouse
-
Contact:
- Francoise HUGUET, Dr
-
Tours, France
- Recruiting
- Chu Tours
-
Contact:
- Antoine MACHET, Dr
-
Versailles, France
- Recruiting
- CH Versailles
-
Contact:
- Philippe ROUSSELOT, Dr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patient ≥ 18 year-old.
- Diagnosis of chronic phase CML according to WHO 2016 criteria with a typical BCR::ABL1 rearrangement (e13a2 or e14a2)
- Duration of treatment by Imatinib ≥ 4 years / ITK2G ≥ 3 years and no change of TKI or decrease in dosage in the last 6 months prior to inclusion
- Deep Molecular Response (DMR) duration ≥ 1 year
- Absence of contraindication to the continuation of the same TKI for 12 months at the same dosage according to international recommendations nd the PCR of each TKI:
Imatinib (≥ 300 mg/j) Dasatinib (≥ 50 mg/j) Nilotinib (≥ 300 mg/j) Bosutinib (≥ 200 mg/j)
- Patient not participating in another interventional study for the duration of the interventional study
- Sexually active men should use effective contraception when taking Dasatinib
- Having an health insurance
- Having signed the consent form
Non-Inclusion Criteria:
- Patients with progressive severe pathology of poor prognosis immediately compromising participation in the entire study and/or with uncontrolled chronic pathology
- ECOG ≥ 3
- Prior resistance to TKI
- Patients who have already experienced an attempt of TKI cessation
- Patients with a malignant tumour that has been treated with chemotherapy within 2 months of inclusion or undergoing chemotherapy or that will be treated with post-inclusion chemotherapy
- Protected person
- Pregnant women or women of childbearing age without appropriate contraceptive measures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: continued treatment with TKI at 50% dose reduction
continued treatment with TKI at 50% dose reduction compared to dosing received at randomization and then stopped treatment 12 months after randomization
|
continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
|
Active Comparator: continuation of TKI treatment without dose change
continued treatment with TKI at same dose compared to dosing received at randomization and then stopped treatment 12 months after randomization
|
continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients in treatment free Remission (TFR) 24 months after treatment discontinuation in patients.Treatment-Free Remission (TFR) is defined as patients with Major Molecular Response (MMR) or better (BCR-ABL level ≤ 0.1% IS).
Time Frame: 24 months after treatment discontinuation
|
Percentage of patients in treatment free Remission (TFR) 24 months after treatment discontinuation in patients is calculated by dividing the number of patients with no loss of MMR-Major Molecular Response (BCR-ABL level ≤ 0.1% IS) on the total number of patients.
|
24 months after treatment discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in proportions (%) at randomization and 12 months post randomization, of innate CD8 T cells among total CD8 T cells
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2023
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2029
Study Registration Dates
First Submitted
February 9, 2023
First Submitted That Met QC Criteria
February 21, 2023
First Posted (Actual)
March 3, 2023
Study Record Updates
Last Update Posted (Actual)
March 20, 2024
Last Update Submitted That Met QC Criteria
March 19, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AITIK
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
PETHEMA FoundationCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
Emory UniversityTerminatedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States
Clinical Trials on treatment of TKI in CML
-
Assiut UniversityUnknownChronic Myeloid Leukemia Patients
-
Fujian Cancer HospitalRecruitingThyroid Cancer | Health Related Quality of Life | Tyrosine Kinase InhibitorChina
-
Azienda Ospedaliera San Giovanni BattistaCompleted
-
IpsenCompletedLocally Advanced or Metastatic Renal Cell CarcinomaUnited States
-
European LeukemiaNetCompletedChronic Myeloid LeukemiaFrance, Denmark, Norway, Sweden, Czechia, Portugal, Germany, Netherlands, Finland, Greece
-
University of Health Sciences LahoreRecruitingTreatment of Refractory GlaucomaPakistan
-
University Hospital, BordeauxRecruitingMetastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC ScoreFrance
-
North-Western State Medical University named after...CompletedEdentulous | Teeth Replacement | Bounded Edentulous Space
-
Affiliated Hospital of Nantong UniversityRecruiting
-
University Hospital, ToulouseTerminatedAcute Ischemic StrokeFrance